共 50 条
- [1] Efficacy and Safety of Apatinib in Relapsed or Refractory Diffuse Large B Cell Lymphoma: An Open-Label, Single-Arm, Prospective StudyBLOOD, 2019, 134Ma, XinranLi, LingZhang, LeiLi, XinFu, XiaoruiWang, XinhuaWu, JingjingZhang, XudongFeng, XiaoyanZhou, ZhiyuanChang, YuLi, ZhaomingYoung, Ken H.Zhang, Mingzhi
- [2] Loncastuximab tesirine in Chinese patients with relapsed or refractory diffuse large B-cell lymphoma: a multicenter, open-label, single-arm, phase II trialHAEMATOLOGICA, 2025, 110 (03) : 683 - 692Lin, NingjingSun, XiuhuaZhou, HuiZou, LiqunZhou, KeshuLiu, LihongYang, HaiyanHu, KaiCai, QingqingLiu, YaoJin, JieZhang, LilingLi, WenyuGuo, YeYang, WeiLuo, FengWang, ZhenguangZhu, RongYang, LeiSong, DanSong, YuqinZhu, Jun
- [3] Apatinib in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma: A Phase II, Open-Label, Single-Arm, Prospective StudyDRUG DESIGN DEVELOPMENT AND THERAPY, 2020, 14 : 275 - 284Ma, XinranLi, LingZhang, LeiFu, XiaoruiLi, XinWang, XinhuaWu, JingjingSun, ZhenchangZhang, XudongFeng, XiaoyanChang, YuZhou, ZhiyuanNan, FeifeiZhang, JiemingLi, ZhaomingZhang, Mingzhi
- [4] Orelabrutinib for the treatment of relapsed or refractory MCL: a phase 1/2, open-label, multicenter, single-arm studyBLOOD ADVANCES, 2023, 7 (16) : 4349 - 4357Deng, Li-JuanZhou, Ke-ShuLiu, Li-HongZhang, Ming-ZhiLi, Zhi-MingJi, Chun-YanXu, WeiLiu, TingXu, BingWang, XinGao, Su-JunZhang, Hui-LaiHu, YuLi, YanCheng, YingYang, Hai-YanCao, Jun-NingZhu, Zun-MinHu, Jian-DaZhang, WeiJing, Hong-MeiDing, Kai-YangZhang, Xiang-YangZhao, Ren -BinZhang, BinTian, Ya -MinSong, Yong-PingSong, Yu-QinZhu, Jun
- [5] Safety and Efficacy of Orelabrutinib Monotherapy in Chinese Patients with Relapsed or Refractory Mantle Cell Lymphoma: A Multicenter, Open-Label, Phase II StudyBLOOD, 2019, 134Song, YuqinSong, YongpingLiu, LihongZhang, MingzhiLi, ZhimingJi, ChunyanXu, WeiLiu, TingXu, BingWang, XinGao, SujunZhang, HuilaiHu, YuLi, YanCheng, YingYang, HaiyanCao, JunningZhu, ZunminHu, JiandaZhang, WeiJing, HongmeiDing, KaiyangLu, ZhengguangZhang, BinZhao, RenbinXu, ZhixinZhu, Jun
- [6] Efficacy and Safety of Lenalidomide, Anti-PD-1 Antibody Combined with Orelabrutinib or Rituximab in the Treatment of Patients with Relapsed/Refractory Diffuse Large B-Cell LymphomaBLOOD, 2022, 140 : 3769 - 3770Qing, MiaoHuang, YongfenChen, CanWang, LinglingFeng, JunXu, ChuanhaiCheng, YuexinDong, JianmingZhang, LinlinXu, Hao
- [7] Efficacy and safety of lenalidomide in relapsed/refractory diffuse large B-cell lymphomaANNALS OF ONCOLOGY, 2008, 19 : 150 - 150Habermann, T.Lossos, I.Justice, G.Tuscano, J.Cole, C.Vose, J.Pietronigro, D.Takeshita, K.Ervin-Haynes, A.Zeldis, J.Wiernik, P.
- [8] Single-Arm Phase II Study of MOR208 Combined with Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: L-MindBLOOD, 2018, 132Salles, Gilles AndreDuell, JohannesGonzalez-Barca, EvaJurczak, WojciechLiberati, Anna MarinaNagy, ZsoltObr, AlesGaidano, GianlucaAndre, MarcKalakonda, NageshDreyling, MartinZinzani, Pier LuigiDirnberger-Hertweck, MarenWeirather, JohannesAmbarkhane, SumeetMaddocks, Kami J.
- [9] Single-Arm Phase II Study of MOR208 Combined with Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: L-MindBLOOD, 2017, 130Salles, Gilles AndreDuell, JohannesGonzalez-Barca, EvaJurczak, WojciechLiberati, Anna MarinaNagy, ZsoltPapajik, TomasGaidano, GianlucaAndre, MarcKalakonda, NageshDreyling, MartinZinzani, Pier LuigiAmbarkhane, SumeetWeirather, JohannesDirnberger-Hertweck, MarenMaddocks, Kami J.
- [10] Geptanolimab in Chinese patients with relapsed or refractory primary mediastinal large B-cell lymphoma: Results from a multicenter, open-label, single-arm phase II trialANNALS OF ONCOLOGY, 2021, 32 : S775 - S776Shi, Y-K.Cui, J.Zhou, H.Zhang, X.Zou, L. Q.Liu, H.Zhang, H.Li, X.Zhang, W.Zhou, F.Zhong, L.Jin, C.Zhang, H.Peng, Z.Gao, Y.Cao, J.Ma, T.